In the BioHarmony Drug Report Database

"Preview" Icon

Lasmiditan

Reyvow (lasmiditan) is a small molecule pharmaceutical. Lasmiditan was first approved as Reyvow on 2020-01-31. It is used to treat migraine with aura and migraine without aura in the USA. It is known to target 5-hydroxytryptamine receptor 1F. Reyvow’s patent is valid until 2037-12-05 (FDA).

 

Trade Name

 

Reyvow
 

Common Name

 

lasmiditan
 

ChEMBL ID

 

CHEMBL3039520
 

Indication

 

migraine with aura, migraine without aura
 

Drug Class

 

Antimigraine (5-HT1 receptor agonists)

Image (chem structure or protein)

Lasmiditan structure rendering